Overview
Mesoblast Limited is a biotechnology company headquartered in Australia, primarily focused on developing and commercializing innovative allogeneic cellular medicines for the treatment of severe diseases where inflammation plays a central role. The company specializes in regenerative medicine with a strong emphasis on cell therapies derived from mesenchymal lineage adult stem cells. Mesoblast's key projects include treatments for inflammatory conditions, cardiovascular diseases, and back pain. Notable among these is its advanced heart failure medication, remestemcel-L, aimed at treating pediatric steroid-refractory acute graft versus host disease. The company has established multiple global partnerships to enhance the development and commercial potential of their leading therapeutic candidates, navigating through rigorous clinical trials aiming for regulatory approvals in various major markets.
Basic Stats
The share price of Mesoblast Limited - Depositary Receipt (Common Stock) as of September 5, 2025 is $14.38 / share. This is an increase of 3.98% from the prior week.
The Factor Analysis chart (below right) shows a view of Mesoblast Limited - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 1,279.93 MM |
| Earnings Date | |
| EPS (TTM) | -0.08 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 7.74 |
| Short Shares Avail. | 0.35 MM |
| Short Interest | 2.38 MM |
| Short Float | |
| Days to Cover | 7.07 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | 124.34 % |
| Volatility (1 yr) | 1.33 |
| Beta | 1.26 |
| Sharpe Ratio (1 yr) | 0.90 |
| Sortino Ratio (1 yr) | 1.13 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.15 |
| ROE | -0.21 |
| ROIC | -0.14 |
| CROIC | 0.14 |
| OCROIC | -0.07 |
| Implied Volatility | 76.53 % |
| Put/Call OI Ratio | 0.18 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Mesoblast Limited - Depositary Receipt (Common Stock) is $15.77. The forecasts range from a low of $15.34 to a high of $16.56. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Mesoblast Limited - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-09-21 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2023-09-21 | PIPER SANDLER COMPANIES | Neutral | Neutral | Maintains |
| 2023-09-03 | BELL POTTER SECURITIES | Buy | Hold | Downgrade |
| 2023-08-31 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2023-08-31 | PIPER SANDLER COMPANIES | Overweight | Neutral | Downgrade |
| 2023-08-30 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2023-08-30 | PIPER SANDLER COMPANIES | Overweight | Neutral | Downgrade |
| 2023-08-04 | CHARDAN CAPITAL MARKETS | Sell | Sell | Maintains |
| 2023-08-03 | CHARDAN CAPITAL MARKETS | Sell | Sell | Maintains |
| 2023-07-12 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-07-11 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-05-26 | PIPER SANDLER COMPANIES | Overweight | Overweight | Maintains |
| 2023-05-25 | PIPER SANDLER COMPANIES | Overweight | Overweight | Maintains |
| 2023-03-22 | BARCLAY PEARCE CAPITAL | Buy | Buy | Maintains |
| 2023-03-21 | BARCLAY PEARCE CAPITAL | Buy | Buy | Maintains |
| 2023-02-08 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2023-02-07 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-11-18 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-11-17 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2021-06-03 | MAXIM GROUP | Buy | Buy | Maintains |
| 2021-06-02 | MAXIM GROUP | Buy | Buy | Maintains |
| 2021-01-19 | Jefferies | Buy | Hold | Downgrade |
| 2020-12-22 | Maxim Group | Buy | Hold | Downgrade |
| 2020-12-04 | Chardan Capital | Neutral | Sell | Downgrade |
| 2020-11-20 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-10-22 | RBC Capital | Sector Perform | Initiate | |
| 2020-10-02 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-05-28 | HC Wainwright & Co. | Buy | Reiterate | |
| 2018-07-18 | Maxim Group | Buy | Buy | Maintains |
| 2018-06-07 | H.C. Wainwright | Buy | Initiate | |
| 2018-03-22 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2016-06-14 | Credit Suisse | Outperform | Neutral | Downgrade |
| 2016-03-07 | JP Morgan | Overweight | Neutral | Downgrade |
| 2016-02-19 | Chardan Capital | Neutral | Initiate | |
| 2016-01-20 | Credit Suisse | Outperform | Initiate | |
| 2015-12-08 | JP Morgan | Overweight | Initiate | |
| 2024-07-08 | PIPER SANDLER COMPANIES | Neutral | Neutral | Maintains |
| 2024-04-04 | BELL POTTER SECURITIES | Hold | Buy | Upgrade |
| 2024-02-28 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2023-09-20 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2023-09-20 | PIPER SANDLER COMPANIES | Neutral | Neutral | Maintains |
| 2023-09-02 | BELL POTTER SECURITIES | Buy | Hold | Downgrade |
| 2025-02-07 | Piper Sandler | Overweight | Overweight | Reiterate |
| 2024-12-23 | Jefferies | Buy | Hold | Downgrade |
| 2024-12-19 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-04-06 | PIPER SANDLER COMPANIES | Overweight | Overweight | Maintains |
| 2025-03-05 | JEFFERIES | Hold | Hold | Maintains |
| 2025-02-27 | MAXIM GROUP | Buy | Buy | Maintains |
| 2025-02-26 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2024-12-19 | PIPER SANDLER COMPANIES | Neutral | Overweight | Upgrade |
| 2024-12-18 | MAXIM GROUP | Buy | Buy | Maintains |
| 2024-08-28 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-07-18 | Jefferies | Buy | Hold | Downgrade |
| 2025-07-17 | JEFFERIES | Hold | Hold | Maintains |
| 2025-07-17 | CANTOR FITZGERALD | Overweight | Overweight | Maintains |
| 2025-07-17 | BELL POTTER SECURITIES | Buy | Buy | Maintains |
| 2025-07-08 | PIPER SANDLER COMPANIES | Overweight | Overweight | Maintains |
| 2025-07-02 | MAXIM GROUP | Buy | Buy | Maintains |
